Skip to content

ALNY

Alnylam Pharmaceuticals, Inc.

Revenue to net income

Key figures

MetricLast 12 months5-year CAGR
Revenue$5.0B+49.8%
Gross profit$3.9B+48.9%
Operating income$978M—
Net income$2.6B—
EPS$19.23—
Free cash flow$752M—